COST-EFFECTIVENESS ANALYSIS OF TREATMENT WITH ABOBOTULINUMTOXINA COMPARED TO BEST SUPPORTIVE CARE IN PATIENTS WITH UPPER LIMB SPASTICITY IN SWEDEN

被引：0
|
作者：
Forsmark, A. [1 ]
Danchenko, N. [2 ]
Ertzgaard, P. [3 ]
Lundkvist, J. [4 ]
Rosengren, L. [5 ]
机构：
[1] Nord Hlth Econ, Gothenburg, Sweden
[2] Ipsen Pharma, Boulogne, France
[3] Linkoping Univ, Fac Hlth Sci, Linkoping, Sweden
[4] Ipsen Pharma, Uppsala, Sweden
[5] Ipsen Pharma, Kista, Sweden
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.2024
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND58
引用
收藏
页码：S338 / S339
页数：3
相关论文
共 50 条
  • [1] Cost-effectiveness of abobotulinumtoxinA plus best supportive care compared with best supportive care alone for early treatment of adult lower limb spasticity following an acute event
    Moore, Peter
    Danchenko, Natalya
    Weidlich, Diana
    Tijerina, Alejandra Rodarte
    PLOS ONE, 2024, 19 (02):
  • [2] Systematic review and cost-effectiveness analysis of the treatment of post-stroke spasticity with abobotulinumtoxinA compared to physiotherapy
    Rodriguez, Maria Errea
    Fernandez, Maria
    del Llano, Juan
    Nuno-Solinis, Roberto
    FARMACIA HOSPITALARIA, 2023, 47 (05) : T201 - T209
  • [3] Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK
    Johnston, Karissa
    Powell, Lauren C.
    Popoff, Evan
    L'Italien, Gil J.
    Pawinski, Robert
    Ahern, Aideen
    Large, Sam
    Tran, Thang
    Jenkins, Aaron
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 627 - 643
  • [4] Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK
    Johnston, K.
    Powell, L.
    Popoff, E.
    L'Italien, G.
    Pawinski, R.
    Ahern, A.
    Large, S.
    Tran, T.
    Jenkins, A.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [5] Effectiveness of AbobotulinumtoxinA in Post-stroke Upper Limb Spasticity in Relation to Timing of Treatment
    Wissel, Joerg
    Fheodoroff, Klemens
    Hoonhorst, Maurits
    Muengersdorf, Martina
    Gallien, Philippe
    Meier, Niklaus
    Hamacher, Juergen
    Hefter, Harald
    Maisonobe, Pascal
    Koch, Manuel
    FRONTIERS IN NEUROLOGY, 2020, 11
  • [6] Comparative efficacy, safety, and cost-effectiveness of abobotulinumtoxinA and onabotulinumtoxinA in children with upper limb spasticity: a systematic literature review, indirect treatment comparison, and economic evaluation
    Danchenko, N.
    Johnston, K. M.
    Haeussler, K.
    Whalen, J.
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 949 - 961
  • [7] OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales
    Freemantle, Nick
    Khalaf, Kristin
    Loveman, Clara
    Stanisic, Sanja
    Gultyaev, Dmitry
    Lister, Johanna
    Drake, Marcus
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2016, 17 (07): : 911 - 921
  • [8] OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales
    Nick Freemantle
    Kristin Khalaf
    Clara Loveman
    Sanja Stanisic
    Dmitry Gultyaev
    Johanna Lister
    Marcus Drake
    The European Journal of Health Economics, 2016, 17 : 911 - 921
  • [9] COST-EFFECTIVENESS OF DIFELIKEFALIN COMPARED TO BEST SUPPORTIVE CARE FOR TREATMENT OF CHRONIC KIDNEY DISEASE-ASSOCIATED PRURITUS IN AUSTRALIA
    Jackson, D.
    Ratkovic, M.
    Tilden, D.
    Soro, M.
    Schaufler, T.
    Grava, A.
    Harsley, S.
    Brydon, S.
    VALUE IN HEALTH, 2024, 27 (12) : S179 - S179
  • [10] The cost-effectiveness of abobotulinumtoxinA (Dysport) and onabotulinumtoxinA (Botox) for managing spasticity of the upper and lower limbs, and cervical dystonia
    Danchenko, Natalya
    Johnston, Karissa M.
    Whalen, John
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 919 - 929
12345